SynAct (Q3 Update): ADVANCE Approaching Full Recruitment - Redeye
Bildkälla: Stockfoto

SynAct (Q3 Update): ADVANCE Approaching Full Recruitment - Redeye

Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025. This means topline data will be available in H1 2026, a major catalyst. The company is funded into 2027.

Redeye reviews SynAct Pharma's Q3 report. The ADVANCE study is progressing and on track to enrol all patients before year-end 2025. This means topline data will be available in H1 2026, a major catalyst. The company is funded into 2027.
Börsvärldens nyhetsbrev